The Annual European Congress of Rheumatology: recent advances in the treatment of rheumatic diseases

Bibliography

• LANDEWE RB, BOERS M, VERHOEVEN AC et al: COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritic Rheum. (2002) 46:347–356.
   PubMed Web of Science ®Google Scholar
• VAN EVERDINGEN AA, JACOBS JW, SIEWERT S, VAN REESEMA DR, BIJLSMA JW: Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann. Intern. Med. (2002) 136:1–12.
   PubMed Web of Science ®Google Scholar
• KEYSTONE EC, KAVANAUGH AF, SHARP JT et al.: Adalimumab inhibits the progression of structural joint damage in patients with active RA. Ann. Rheum. Dis. (2003) 62:64.
   Web of Science ®Google Scholar
• GENOVESE MC, BATHON JM, MARTIN RW et al: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritic Rheum. (2002) 46:1443–1450.
   PubMed Web of Science ®Google Scholar
• SMOLEN SJ, EMERY P, BATHON JMet al.: Treatment of early rheumatoid arthritis with infliximab plus methotrexate or methotrexate alone: preliminary results of the ASPIRE Trial. Ann. Rheum. Dis. (2003) 62:64.
   Google Scholar
• STAHL H, SZCZEPANSKI L, SZECHINSKI J et al.: Ritwdmab in RA: efficacy and safety from a randomised controlled trial. Ann. Rheum. Dis. (2003) 62:65.
   PubMed Web of Science ®Google Scholar
• •A monoclonal anti-CD 20 antibody combined with MTX is effective in refactory cases of RA.
   Google Scholar
• LUGGEN ME, SCHECHTMAN J, KIVITZ A et al.: Results of a Phase II, double-blind, randomized study of a nondepleting antiCD4+ monoclonal antibody (clenwdmab) given in combination with methotrexate (MTX) in patients with moderate-to-severe rheumatoid arthritis (RA). Ann. Rheum. Dis. (2003) 62:99.
   Web of Science ®Google Scholar
• SCHNEIDER M, STAHL H, VAISHNAW A, PODBREBARAC T, BRAUN J: A pilot study of the safety and efficacy of alfacept in subjects with active rheumatoid arthritis on methotrexate. Ann. Rheum. Dis. (2003) 62:99–100.
   Web of Science ®Google Scholar
• MAINI R, CHARISMA STUDY GROUP: A double-blind, randomised parallel group, controlled dose ranging study of the safety, tolerability, pharmacokinetics and efficacy of repeat doses of MRA given alone or in combination with methotrexate in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62:64.
   Web of Science ®Google Scholar
• BASLUND B, TVEDE N, DANNESKIOLD-SAMSOE B et al.: First use of a human monoclonal antibody against IL-15 (HUMAX-1L15) in patients with rheumatoid arthritis (RA): Results of a double-blind, placebo-controlled Phase I/II trial. Ann. Rheum. Dis. (2003) 62:66.
   Web of Science ®Google Scholar
• GENOVESE MC, COHEN SB, MORELAND LW et al: A randomised double-blind controlled study evaluating the safety and efficacy of etanercept versus etanercept plus anakinra in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62:66.
   Web of Science ®Google Scholar
• ••Important study showing similar efficacybut an increased rate of infections during treatment with etanercept plus anakinra versus etanercept alone.
   Google Scholar
• KARANIKOLAS G, CHARALAMBOPOULOS D, ANDRIANAKOS A et al: Cyclosporin versus leflunomide versus combination of the two drugs in rheumatoid arthritis: long-term optimal results of combination treatment from an open randomized study. Ann. Rheum. Dis. (2003) 62:100.
   PubMed Web of Science ®Google Scholar
• BRAUN J, BRANDT J, LISTING J et al: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicenter trial. Lancet (2002) 359:1187–1193.
   PubMed Web of Science ®Google Scholar
• GORMAN JD, SACK KE, DAVIS JC Jr: Treatment of ankylosing spondylitis by inhibition of tumour necrosis factor alpha. N Engl. J. Med. (2002) 346:1349–1356.
   PubMed Web of Science ®Google Scholar
• DAVIS JC, VAN DER HEIJDE D, BRAUN J et al.: Etanercept (Enbrel) improves signs and symptoms of ankylosing spondylitis: results of a Phase III multicenter clinical trial. Ann. Rheum. Dis. (2003) 62:65.
   Google Scholar
• CALIN A, DIIJKMANS B, EMERY P et al.: A multicenter, placebo-controlled trial of enbrel in ankylosing spondylitis. Ann. Rheum. Dis. (2003) 62:95.
   PubMed Web of Science ®Google Scholar
• BRAUN J, PHAM T, SIEPER J et al: International ASAS Consensus Statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann. Rheum. Dis. (2003) 62:55.
   Web of Science ®Google Scholar
• KALTWASSER J, NASH P, GLADMAN D et al.: Leflunomide in the treatment of psoriatic arthritis and psoriasis: Data from a double-blind randomized, placebo-controlled clinical trial. Ann. Rheum. Dis. (2003) 62:90.
   PubMed Web of Science ®Google Scholar
• •Leflunomide improves arthritis and skin manifestations in psoriasis.
   Google Scholar
• ANTONI CE, KAVANAUGH AF, KIRKHAM B et al.: The infliximab multinational psoriatic arthritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy. Ann. Rheum. Dis. (2003) 62:90.
   PubMed Web of Science ®Google Scholar
• MEASE PJ, GOFFE BS, METZ Jet al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356:385–390.
   Google Scholar
• ORY P, SHARP JT, SALONEN D et al: Etanercept (Enbrel) inhibits radiographic progression in patients with psoriatic arthritis. Ann. Rheum. Dis. (2003) 62:92–93.
   PubMed Web of Science ®Google Scholar
• HANNONEN P, MALMINIEMI K, YLI-KERTTULA U, ISOMERI R, ROPONEN P: A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br. Rheumatol. (1998) 37:1279–1286.
   PubMedGoogle Scholar
• ARNOLD LM, HESS EV, HUDSON JI et al.: A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am. J. Med. (2002) 112:191–197.
   PubMed Web of Science ®Google Scholar
• SCHARF MB, BAUMANN M, BERKOVITZ D: The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. Rheumatol. (2003) 30:1070–1074.
   Web of Science ®Google Scholar
• BENNETT RM, KAMIN M, KARIM R, ROSENTHAL N: Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am. J. Med. (2003) 114:537–545.
   PubMed Web of Science ®Google Scholar
• MEASE P, CROFFORD LJ, RUSSEL I et al.: Pregabalin improves pain, sleep and fatigue associated with fibromyalgia syndrome (FMS) in a multicenter, randomized, placebo-controlled, monotherapy trial. Ann. Rheum. Dis. (2003) 62:77.
   PubMed Web of Science ®Google Scholar
• HOUSSIAU FA, VASCONCELOS C, D'CRUZ D et al.: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. (2002) 46:2121–2131.
   Google Scholar
• HOUSSIAU F, COSYNS JP, CERVERA R:The Euro-Lupus Trial: 5-year follow-up. Ann. Rheum. Dis. (2003) 62:81.
   PubMed Web of Science ®Google Scholar
• MARIETTE X, RAVAUD P, STEINFELD S et al.: Absence of efficiency of infliximab in primary Sjoegren's syndrome: preliminary results of the TRIPPS study: trial of remicade in primary sjoegren's syndrome. Ann. Rheum. Dis. (2003) 62:66.
   Web of Science ®Google Scholar
• ZANDBELT M, DE WILDE PCM, VAN DAMME PA et al.: Etanercept in the treatment of primary sjoegren's syndrome: a pilot study. Ann. Rheum. Dis. (2003) 62:83.
   Google Scholar
• •In contrast to findings from a smaller previous trial, infliximab was not effective in Sjoegren's syndrome in this large trial.
   Google Scholar
• DE GROOT K: Randomised controlled trials and new drugs. Ann. Rheum. Dis. (2003) 62:53.
   Web of Science ®Google Scholar
• HELLMICH B, CSERNOK E, GROSS W:20 Years with ANCA (antineutrophil cytoplasmic antibodies): from seromarker to major pathogenic player in vasculitis. J. Leak. Biol. (2003) 74:1–2..
   PubMed Web of Science ®Google Scholar